Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion

Linda Stein Gold; Mark Lebwohl; Neal  Bhatia; Douglas DiRuggiero; Abby Jacobson; Radhakrishnan Pillai

doi:10.25251/skin.4.supp.79

Linda Stein Gold

Henry Ford Hospital, Detroit, MI

Mark Lebwohl

Icahn School of Medicine at Mount Sinai, New York, NY

Neal Bhatia

Therapeutics Clinical Research, San Diego, CA

Douglas DiRuggiero

Skin Cancer & Cosmetic Dermatology, Rome, Georgia

Abby Jacobson

Ortho Dermatologics*, Bridgewater, NJ

Radhakrishnan Pillai

Bausch Health US, LLC*, Petaluma, CA

Keywords

Psoriasis, Plaque Psoriasis, Topical, Corticosteroid, Halobetasol, Retinoid, Tazarotene, Cessation, Treatment Success

Abstract

Abstract not available.

References

1. Nestle FO, et al. N Engl J Med. 2009;361(5):496-509.

2. Benhadou F, et al. Dermatology. 2019;235(2):91-100.

3. Tanghetti E, et al. J Dermatolog Treat. 2019:1‑8.

4. Chandraratna RA. J Am Acad Dermatol. 1997;37(2 Pt 3):S12-17.

5. Duvic M, et al. J Am Acad Dermatol. 1997;37(2 Pt 3):S18-24.

6. Tanghetti E, et al. J Drugs Dermatol. 2018;17(12):1280-1287.

Poster PDF

Published

Oct 27, 2020

DOI https://doi.org/10.25251/skin.4.supp.79

How to Cite

[1]

Stein Gold, L., Lebwohl, M., Bhatia, N. , DiRuggiero, D., Jacobson, A. and Pillai, R. 2020. Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion. SKIN The Journal of Cutaneous Medicine. 4, 6 (Oct. 2020), s79. DOI:https://doi.org/10.25251/skin.4.supp.79.

Issue

Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)

Section

Poster Presentations from FC20 Clinical Dermatology Conference®: Psoriasis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Author Biographies

Abby Jacobson, Ortho Dermatologics*, Bridgewater, NJ

*Bausch Health US, LLC is an affiliate of Bausch Health Companies Inc.

Radhakrishnan Pillai, Bausch Health US, LLC*, Petaluma, CA

Ortho Dermatologics is a division of Bausch Health US, LLC

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Abby Jacobson, Ortho Dermatologics*, Bridgewater, NJ

Radhakrishnan Pillai, Bausch Health US, LLC*, Petaluma, CA

Most read articles by the same author(s)